[go: up one dir, main page]

CL2019001618A1 - Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar. - Google Patents

Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.

Info

Publication number
CL2019001618A1
CL2019001618A1 CL2019001618A CL2019001618A CL2019001618A1 CL 2019001618 A1 CL2019001618 A1 CL 2019001618A1 CL 2019001618 A CL2019001618 A CL 2019001618A CL 2019001618 A CL2019001618 A CL 2019001618A CL 2019001618 A1 CL2019001618 A1 CL 2019001618A1
Authority
CL
Chile
Prior art keywords
relief
prevention
treatment
bipolar disorder
carbamate compounds
Prior art date
Application number
CL2019001618A
Other languages
English (en)
Inventor
Yu Jin Shin
Sei Myoung Han
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of CL2019001618A1 publication Critical patent/CL2019001618A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA AL USO PARA EL PROPÓSITO DE PREVENIR, ALIVIAR O TRATAR EL TRASTORNO BIPOLAR AL ADMINISTRAR UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN COMPUESTO DE CARBAMATO DE LA SIGUIENTE FÓRMULA QUÍMICA 1.
CL2019001618A 2016-12-14 2019-06-12 Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar. CL2019001618A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20160170224 2016-12-14

Publications (1)

Publication Number Publication Date
CL2019001618A1 true CL2019001618A1 (es) 2019-08-23

Family

ID=62559442

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001618A CL2019001618A1 (es) 2016-12-14 2019-06-12 Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.

Country Status (13)

Country Link
US (1) US11571410B2 (es)
EP (1) EP3556366A4 (es)
JP (1) JP7208139B2 (es)
KR (1) KR102635938B1 (es)
CN (1) CN110290788A (es)
AU (1) AU2017374458B2 (es)
BR (1) BR112019011930A2 (es)
CA (1) CA3046297A1 (es)
CL (1) CL2019001618A1 (es)
IL (1) IL267195B2 (es)
MX (1) MX2019006940A (es)
WO (1) WO2018111008A1 (es)
ZA (1) ZA201903747B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113242735A (zh) * 2018-09-21 2021-08-10 爱思开生物制药株式会社 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作
MX2021003203A (es) * 2018-09-21 2021-05-27 Sk Biopharmaceuticals Co Ltd Compuesto de carbamato y uso de la formulacion que comprende el mismo en prevenir, aliviar, o tratar trastorno de estres agudo o trastorno de estres post-traumatico.
JP2023503088A (ja) * 2019-11-22 2023-01-26 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物を含む経口用医薬組成物及びその製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU741532B2 (en) 1997-08-14 2001-12-06 F. Hoffmann-La Roche Ag Heterocyclic vinylethers against neurological disorders
KR100843703B1 (ko) 2000-07-21 2008-07-04 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 양극성 장애에서의 조증을 치료하기 위한 벨프로익산 및 2-벨프로에닉산 아미드 유도체의 용도
CZ20032300A3 (cs) 2001-02-27 2005-01-12 Ortho-Mcneil Pharmaceutical, Inc. Léčivo pro prevenci nebo léčbu bipolárních chorob
EP1368021B1 (en) * 2001-02-27 2007-11-14 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
KR20130030305A (ko) 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
US20080103199A1 (en) * 2006-10-31 2008-05-01 Haas Magali Treatment of pervasive developmental disorders
US8501436B2 (en) 2009-06-22 2013-08-06 Sk Biopharmaceuticals Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
PL3180329T3 (pl) 2014-08-15 2020-08-24 Janssen Pharmaceuticals, Inc. Triazole jako inhibitory receptora NR2B

Also Published As

Publication number Publication date
EP3556366A1 (en) 2019-10-23
ZA201903747B (en) 2021-01-27
KR102635938B1 (ko) 2024-02-13
MX2019006940A (es) 2019-09-06
IL267195B1 (en) 2024-01-01
CN110290788A (zh) 2019-09-27
WO2018111008A1 (ko) 2018-06-21
AU2017374458B2 (en) 2023-03-02
AU2017374458A1 (en) 2019-07-04
CA3046297A1 (en) 2018-06-21
US20190314337A1 (en) 2019-10-17
JP2020502106A (ja) 2020-01-23
KR20190087572A (ko) 2019-07-24
RU2019121913A3 (es) 2021-04-21
EP3556366A4 (en) 2020-06-17
IL267195B2 (en) 2024-05-01
IL267195A (es) 2019-07-31
BR112019011930A2 (pt) 2019-10-29
JP7208139B2 (ja) 2023-01-18
US11571410B2 (en) 2023-02-07
RU2019121913A (ru) 2021-01-15

Similar Documents

Publication Publication Date Title
MX2018011992A (es) Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos.
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
CL2019000266A1 (es) Composición de cannabis.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
ECSP20035222A (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
JOP20210050A1 (ar) معدلات تعبير pnpla3
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
DOP2020000077A (es) Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas
CL2020002347A1 (es) Nuevo compuesto y composición farmacéutica que lo comprende
CO2017001076A2 (es) Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam
CL2019001623A1 (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor.
MX2017013879A (es) Composiciones que comprenden anakinra.